Indaptus Therapeutics Aktie - INDP

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,8068

Gebot

0,7769

Fragen

0,85

Volumen

29.088

0,7497 Tagesbereich 0,85

0,7012 52-Wochen-Bereich 3,10

Marktkapitalisierung

8,227M

Handelsende

0,84

Handelsbeginn

0,822

Letzte Trade

0.8397

Letzter Handelszeitpunkt

23:23:08

Finanzvolumen

US$ 23.442

VWAP

0,805885

Durchschnittliches Volumen (3 Mio.)

22.252

Ausgegebene Aktien

10.196.884

Dividendenrendite

Kurs-Gewinn-Verhältnis

-6,37

Gewinn pro Aktie (EPS)

-1,51

Erlöse

Nettogewinn

-15,42M

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, ... Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Mehr anzeigen

Sektor

Medicinal Chems,botanicl Pds

Branche

Medicinal Chems,botanicl Pds

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Indaptus Therapeutics Inc is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker INDP. The last closing price for Indaptus Therapeutics was US$0,84. Over the last year, Indaptus Therapeutics shares have traded in a share price range of US$ 0,7012 to US$ 3,10.

Indaptus Therapeutics currently has 10.196.884 shares in issue. The market capitalisation of Indaptus Therapeutics is US$8,57 million. Indaptus Therapeutics has a price to earnings ratio (PE ratio) of -6.37.

Form 8-K - Current report

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1...

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Meet with Indaptus Therapeutics’ CEO Jeffrey MecklerRegister at INDP-KEYS.TribePublic.com NEW YORK, March 12...

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.0431	-5.07118484528	0.8499	0.86	0.7601	11935	0.82446225	CS
4	0.0568	7.57333333333	0.75	0.86	0.7012	16948	0.79263835	CS
12	-0.2021	-20.0317177124	1.0089	1.06	0.7012	22252	0.85095686	CS
26	-0.7232	-47.2679738562	1.53	2.08	0.7012	68742	1.56683561	CS
52	-1.2032	-59.8606965174	2.01	3.1	0.7012	44766	1.75943968	CS
156	-2.8532	-77.956284153	3.66	4.25	0.7012	72306	2.56135425	CS
260	-9.2932	-92.0118811881	10.1	28.8299	0.7012	365456	9.07352196	CS

INDP - Frequently Asked Questions (FAQ)

What is the current Indaptus Therapeutics share price?

The current share price of Indaptus Therapeutics is US$ 0,8068

How many Indaptus Therapeutics shares are in issue?

Indaptus Therapeutics has 10.196.884 shares in issue

What is the market cap of Indaptus Therapeutics?

The market capitalisation of Indaptus Therapeutics is USD 8,57M

What is the 1 year trading range for Indaptus Therapeutics share price?

Indaptus Therapeutics has traded in the range of US$ 0,7012 to US$ 3,10 during the past year

What is the PE ratio of Indaptus Therapeutics?

The price to earnings ratio of Indaptus Therapeutics is -6,37

What is the reporting currency for Indaptus Therapeutics?

Indaptus Therapeutics reports financial results in USD

What is the latest annual profit for Indaptus Therapeutics?

The latest annual profit of Indaptus Therapeutics is USD -15,42M

What is the registered address of Indaptus Therapeutics?

The registered address for Indaptus Therapeutics is 1007 NORTH ORANGE STREET, 10TH FLOOR, WILMINGTON, DELAWARE, 19801

Which industry sector does Indaptus Therapeutics operate in?

Indaptus Therapeutics operates in the MEDICINAL CHEMS,BOTANICL PDS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
RDUSRadius Recycling Inc	US$ 28,75 (110,47%)	31,16k
MRMMEDIROM Healthcare Technologies Inc	US$ 1,10 (77,42%)	3,76M
AAOIApplied Optoelectronics Inc	US$ 26,30 (65,72%)	2,21M
BTOGBit Origin Ltd	US$ 0,3714 (36,09%)	2,7M
PRPLPurple Innovation Inc	US$ 0,83 (25,09%)	3,47M
MKDWMKDWELL Tech Inc	US$ 0,3214 (-21,15%)	4,13k
NAYANAYA Biosciences Inc	US$ 0,255 (-20,59%)	102,29k
LGCBLinkage Global Inc	US$ 0,1831 (-19,83%)	5,8M
RGCRegencell Bioscience Holdings Ltd	US$ 11,30 (-19,80%)	1,81M
HMRHeidmar Maritime Holdings Corporation	US$ 3,46 (-15,20%)	1,54M
ICONIcon Energy Corporation	US$ 0,126 (-7,35%)	9,7M
LGCBLinkage Global Inc	US$ 0,1831 (-19,83%)	5,8M
ADTXAditxt Inc	US$ 0,0329 (-1,50%)	5,01M
DGLYDigital Ally Inc	US$ 0,083 (4,53%)	4,26M
HEPAHepion Pharmaceuticals Inc	US$ 0,0368 (-2,65%)	3,89M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Indaptus Therapeutics Inc (INDP)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Indaptus Therapeutics Inc

INDP Neueste Nachrichten

Form 8-K - Current report

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Form EFFECT - Notice of Effectiveness

INDP - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Indaptus Therapeutics Inc (INDP) Börsenkurse

Indaptus Therapeutics Inc (INDP)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Indaptus Therapeutics Inc

INDP Neueste Nachrichten

Form 8-K - Current report

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Form EFFECT - Notice of Effectiveness

INDP - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen